Press releaseGlobe Newswire
Context Therapeutics
CNTX · NASDAQ
$0.2438+$0.0054 (+2.27%)TodayMarket closed ·
Prev close $0.2384
Latest news
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NewsTanya Rawat
Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move
- Press releaseGlobe Newswire
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
- Press releaseGlobe Newswire
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes
- NewsVandana Singh
Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study
- Press releaseGlobe Newswire
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
- Press releaseGlobe Newswire
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
- Press releaseGlobe Newswire
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
- Press releaseGlobe Newswire
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
- Press releaseBusiness Wire
Neogen® Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary
- Press releaseGlobe Newswire
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- Press releaseGlobe Newswire
Context Therapeutics Reports Full Year 2025 Operating and Financial Results
- Press releaseGlobe Newswire
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
- Press releaseGlobe Newswire
Context Therapeutics to Participate in Upcoming Investor Conferences
- NewsAvi Kapoor
Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
- Press releaseGlobe Newswire
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
- Press releaseGlobe Newswire
Context Therapeutics to Participate in Upcoming Investor Conferences
- NewsAvi Kapoor
This Synopsys Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
- NewsAvi Kapoor
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
- Press releasePRNewswire
Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment
- Press releaseGlobe Newswire
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
- Press releaseGlobe Newswire
Context Therapeutics to Participate in Upcoming Investor Conferences in November
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.